Cognitive Behavioral Therapy for Sexual Concerns During Perimenopause: A Four Session Study Protocol

Sheryl M Green, Melissa Furtado, Sheryl M Green, Melissa Furtado

Abstract

Background: During the menopausal transition, women often experience physical (e.g., vasomotor symptoms) and emotional (e.g., anxiety and depression) difficulties that significantly impact functioning and overall quality of life. Although sexual concerns (e.g., decreased sexual desire, orgasm), are reported by up to 87% of peri- and post-menopausal women, and are associated with adverse impact on functioning and distress, treatment options that directly target this area are limited, and most often involve medication (e.g., hormone replacement). Effectiveness of these treatments is often defined as improvements in physical symptoms, however, associated psychological and emotional symptoms rarely, if at all, improve. Cognitive behavioral therapy (CBT) has been proposed as a low-risk treatment for menopausal symptoms with studies showing improvement in frequently reported symptoms (e.g., vasomotor symptoms, depression, anxiety, sleep). Sexual concerns, however, have either not been directly targeted at all in current CBT protocols, or the very few protocols that include sexual concerns, demonstrated modest gains in sexual desire. Methods: This protocol paper outlines the development, design, and implementation of a newly developed CBT for sexual concerns trial during perimenopause (CBT-SC-Peri). Although sexual concerns are prevalent during both the peri- and post-menopausal periods, we will be evaluating the effectiveness of a CBT-SC protocol specifically for perimenopausal women as a means of early intervention. The clinical sample will comprise 82 women aged 40-60 years currently in perimenopause, as per the Stages of Reproductive Aging Workshop (STRAW) definition, and medication stable (if applicable). To ensure participants are experiencing clinically significant sexual concerns, a baseline cut-off score of 26 or lower on the Female Sexual Functioning Index will be utilized. Exclusion criteria include participants with psychotic disorders, or current substance and/or alcohol dependence, or severely depressed/suicidal. The CBT-SC-Peri is a weekly, four session treatment, lasting up to 90 min per session and includes psychoeducation and cognitive and behavioral strategies designed to challenge unhelpful beliefs and promote healthy sexual behaviors. As this is an individual CBT protocol, content will be tailored to address the specific problems relevant for each participant. Eligible women will be placed directly into treatment or on a 4-week waitlist and reassessed prior to starting treatment. The primary outcome (sexual satisfaction), as well as secondary outcomes (desire, arousal, relationship satisfaction, body image, vasomotor symptoms, depression, and anxiety) are assessed at baseline, post-waitlist (for those on waitlist), and post-treatment. Discussion: To our knowledge, this will be the first study to investigate the efficacy of a CBT protocol (CBT-SC-Peri) specifically aimed at improving sexual concerns experienced during perimenopause. If effective, this form of treatment may not only be preferred by some, but necessary for others as consumer demand increases for non-pharmacological treatments for perimenopausal symptoms. Further, this protocol can be integrated into perimenopausal care and will be made available by dissemination to healthcare practitioners. Clinical Trial Registration: Trial # NCT04922385 and Accessible at: https://ichgcp.net/clinical-trials-registry/NCT04922385?term=NCT04922385anddraw=2andrank=1.

Keywords: cognitive behavioral therapy; non-pharmacological management; perimenopause; psychological; sexual concerns.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Green and Furtado.

Figures

Figure 1
Figure 1
Flowchart of trial procedures.

References

    1. Baker FC, de Zambotti M, Colrain IM, Bei B. Sleep problems during the menopausal transition: prevalence, impact, and management challenges. Nat Sci Sleep. (2018) 10:73–95. 10.2147/NSS.S125807
    1. Brown WJ, Mishra GD, Dobson A. Changes in physical symptoms during the menopause transition. Int J Behav Med. (2002) 9:53–67. 10.1207/S15327558IJBM0901_04
    1. Nappi RE, Lachowsky M. Menopause and sexuality: prevalence of symptoms and impact on quality of life. Maturitas. (2009) 63:138–41. 10.1016/j.maturitas2009.03.021
    1. Williams RE, Levine KB, Kalilani L, Lewis J, Clark RV. Menopause-specific questionnaire assessment in US population-based study shows negative impact on health-related quality of life. Maturitas. (2009) 62:153–9. 10.1016/j.maturitas.2008.12.006
    1. Nazarpour S, Simbar M, Tehrani FR. Factors affecting sexual function in menopause: a review article. Taiwan J Obstet Gynecol. (2016) 55:480–7. 10.1016/j.tjog.2016.06.001
    1. Lara LA, Useche B, Ferriani RA, Reis RM, de Sá MF, de Freitas MM, et al. . REVIEWS: The effects of hypoestrogenism on the vaginal wall: interference with the normal sexual response. J Sex Med. (2009) 6:30–9. 10.1111/j.1743-6109.2008.01052.x
    1. North American Menopause Society . Menopause Practice: A Clinician's Guide, 6th Edition. Pepper Pike, OH: North American Menopause Society; (2019).
    1. Lindau ST, Gavrilova N. Sex, health, and years of sexually active life gained due to good health: evidence from two US population based cross sectional surveys of ageing. BMJ. (2010) 340:c810. 10.1136/bmj.c810
    1. World Health Organization . Health Topics: Sexual Health. (2012). Available online at: (accessed 16 June, 2021).
    1. Goldstein I. Current management strategies of the postmenopausal patient with sexual health problems. J Sex Med. (2007) 4:235–53. 10.1111/j.1743-6109.2007.00450.x
    1. Simon JA. Identifying and treating sexual dysfunction in postmenopausal women: the role of estrogen. J Womens Health. (2010) 20:1453–65. 10.1089/jwh.2010.2151
    1. Writing Group for the Women's Health Initiative Investigators . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. (2002). 288:321–33. 10.1001/jama.288.3.321
    1. Thornton K, Chervenak J, Neal-Perry G. Menopause and sexuality. Endocrinol Metab Clin North Am. (2015) 44:649–61. 10.1016/j.ecl.2015.05.009
    1. Collaborative Group on Hormonal Factors in Breast Cancer . Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet. (2019). 394:1159–68. 10.1016/S0140-6736(19)31709-X
    1. Islam RK, Bell RJ, Green S, Page MJ, Davis SR. Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomized controlled trial data. Lancet Diabetes Endorcinol. (2019) 7:754–66. 10.1016/S2213-8587(19)30189-5
    1. Cappelletti M, Wallen K. Increasing women's sexual desire: the comparative effectiveness of estrogens and androgens. Horm Behav. (2015) 78:178–93. 10.1016/j.yhbeh.2015.11.003
    1. Khoshbooii R, Hassan SAB, Hamzah MSGB, Baba MB. Effectiveness of group cognitive behavioral therapy on depression among Iranian women around menopause. Aust J Basic Appl Sci. (2011) 5:991–5. 10.3390/ijerph18147711
    1. Balabanovic J, Ayers B, Hunter MS. Cognitive behaviour therapy for menopausal hot flushes and night sweats: a qualitative analysis of women's experiences of group and self-help CBT. Behav Cogn Psychother. (2012) 41:441–57. 10.1017/S1352465812000677
    1. Green SM, Donegan E, Frey BN, Fedorkow DM, Key BL, Streiner DL, et al. . Cognitive behavior therapy for menopausal symptoms (CBT-Meno): a randomized controlled trial. Menopause. (2019) 26:972–80. 10.1097/GME.0000000000001363
    1. Alder J, Eymann Besken K, Armbruster U, Decio R, Gairing A, Kang A, et al. . Cognitive-behavioural group intervention for climacteric syndrome. Psychother Psychosom. (2006) 75:298–303. 10.1159/000093951
    1. Harlow SD, Gass M, Hall JE, Lobo R, Maki P, Rebar RW, et al. . Executive summary of the stages of reproductive aging workshop + 10: addressing the unfinished agenda of staging reproductive aging. Menopause. (2012) 19:387–95. 10.1097/gme.0b013e31824d8f40
    1. Wiegel M, Meston C, Rosen R. The female sexual function index (FSFI): cross- validation and development of clinical cutoff scores. J Sex Marital Ther. (2005) 31:1–20. 10.1080/00926230590475206
    1. Rosen C, Brown J, Heiman S, Leiblum C, Meston R, Shabsigh D, et al. . The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther. (2000) 26:191–208. 10.1080/009262300278597
    1. Pérez-Herrezuelo I, Hita-Contreras F, Martínez-Amat A, Aibar-Almazàn A, Cruz-Díaz D, Wangensteen R, et al. . The female sexual function index: reliability and validity in Spanish postmenopausal women. Menopause. (2019) 26:401–8. 10.1097/GME.0000000000001305
    1. Sand M, Rosen R, Meston C, Brotto LA. The female sexual function index (FSFI): a potential “gold standard” measure for assessing therapeutically-induced change in female sexual function. Fertility. (2009) 92(Suppl):S129. 10.1016/j.fertnstert.2009.07.1173
    1. DeRogatis L, Clayton A, Lewis-D'Agostino D, Wunderlich G, Fu Y. Validation of the female sexual distress scale—revised for assessing distress in women with hypoactive sexual desire disorder. J Sex Med. (2008) 5:357–64. 10.1111/j.1743-6109.2007.00672.x
    1. Goldhammer DL, McCabe MP. Development and psychometric properties of the Female Sexual Desire Questionnaire (FSDQ). J Sex Med. (2011) 8:2512–21. 10.1111/j.1743-6109.2011.02334.x
    1. Greene JG. Constructing a standard climacteric scale. Maturitas. (1998) 29:25–31. 10.1016/s0378-5122(98)00025-5
    1. Vasconcelos-Raposo J, Coelho E, Fernandes HM, Rodrigues C, Moreira H, Teixeira C. Factor structure and normative data of the greene climacteric scale among postmenopausal portuguese women. Maturitas. (2012) 72:256–62. 10.1016/j.maturitas.2012.04.003
    1. Carpenter JS. The Hot Flash Related Daily Interference Scale: a tool for assessing the impact of hot flashes on quality of life following breast cancer. J Pain Symptom Manage. (2001) 22:979–89. 10.1016/s0885-3924(01)00353-0
    1. Carpenter JS, Bakoyannis G, Otte JL, Chen CX, Rand KL, Woods N, et al. . Validity, cutpoints, and minimally important differences for two hot flash related daily interference scales. Menopause. (2017) 24:877–85. 10.1097/GME.0000000000000871
    1. Beck AT, Steer RA, Brown GK. Beck Depression Inventory-II. San Antonio, TX: Psychological Corporation; (1996).
    1. Wang YP, Gorenstein C. Psychometric properties of the Beck Depression Inventory-II: a comprehensive review. Rev Bras Psiquiatr. (2013) 35:416–31. 10.1590/1516-4446-2012-1048
    1. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. (1959) 32:50–5. 10.1111/j.2044-8341.1959.tb00467.x
    1. Maier W, Buller R, Philipp M, Heuser I. The Hamilton Anxiety Scale: reliability, validity and sensitivity to change in anxiety and depressive disorders. J Affect Disord. (1988) 14:61–8. 10.1016/0165-0327(88)90072-9
    1. Funk JL, Rogge RD. Testing the ruler with item response theory: increasing precision of measurement for relationship satisfaction with the Couples Satisfaction Index. J Fam Psychol. (2007) 21:572. 10.1037/0893-3200.21.4.572
    1. Yekta FF, Yaghubi H, Mootabi F, Roshan R, Fesharaki MG, Omidi A. Psychometric characteristics and factor analysis of the Persian version of the couples satisfaction index. Avicenna J Neuro Psycho Physiol. (2017) 4:49–56. 10.32598/ajnpp.4.2.49
    1. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Med Care. (1992) 30:473–83.
    1. Gandek B, Sinclair SJ, Kosinski M, Ware JE, Jr. Psychometric evaluation of the SF-36 Health Survey in Medicare managed care. Health Care Financ Rev. (2004). 25, 5–25.
    1. LoMartire R, Äng BO, Gerdie B, Vixner L. Psychometric properties of Short Form-36 Health Survey, EuroQol 5-dimensions, and Hospital Anxiety and Depression scale in patients with chronic pain. Pain. (2020) 161:83–95. 10.1097/j.pain.0000000000001700
    1. Scheffers M, van Duijn MAJ, Bosscher RJ, Wiersma D, Schoevers RA, van Busschbach JT. Psychometric properties of the Dresden Body Image Questionnaire: a multiple-group confirmatory factor analysis across sex and age in a Dutch non-clinical sample. PLoS ONE. (2017) 12:e0181908. 10.1371/journal.one.0181908
    1. Lev-Ari L, Zohar AH, Bachner-Melman R. Enjoying your body: the psychometric properties of an English version of the Dresden Body Image Questionnaire. Aust J Psychol. (2019) 72:267–75. 10.1111/ajpy.12284
    1. Dennis JP, Vander Wal JS. The cognitive flexibility inventory: instrument development and estimates of reliability and validity. Cognit Ther Res. (2010) 34:241–53. 10.1007/s10608-009-9276-4
    1. Green SM, McCabe RE, Soares CN. The Cognitive Behavioral Workbook for Menopause: A Step-by-Step Program for Overcoming Hot Flashes, Mood Swings, Insomnia, Anxiety, Depression, and Other Symptoms. Oakland, VA: New Harbinger Publications. (2012).
    1. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. (2009) 42:377–81. 10.1016/j.jbi.2008.08.010
    1. Statistics Canada (2010). Available online at: (accessed August 30, 2021).

Source: PubMed

3
Prenumerera